Kiromic BioPharma (KRBP) News Today $0.83 -0.04 (-4.60%) As of 01/21/2025 03:21 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01January 21 at 7:38 PM | uk.finance.yahoo.comKiromic files to raise $17M through uplistingJanuary 21 at 7:38 PM | msn.comKiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01December 12, 2024 | finance.yahoo.comSEC settles charges with Kiromic Biopharma for misleading investors, issues penalties for former execsDecember 3, 2024 | bizjournals.comKiromic BioPharma Announces Settlement of Previously Disclosed SEC InvestigationDecember 3, 2024 | businesswire.comKiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01October 8, 2024 | finance.yahoo.comKiromic BioPharma (OTC:KRBP) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comKiromic BioPharma (OTC:KRBP) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comKiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical TrialOctober 1, 2024 | finance.yahoo.comKiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous RecommendationSeptember 21, 2024 | finance.yahoo.comKiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialSeptember 19, 2024 | finance.yahoo.comKiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialSeptember 19, 2024 | businesswire.comKiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous RecommendationSeptember 19, 2024 | businesswire.comKiromic Biopharma Inc (KRBP)September 13, 2024 | investing.comKiromic BioPharma's Deltacel Receives FDA Fast Track DesignationAugust 14, 2024 | stockhouse.comKiromic reports update from Phase I NSCLC treatment trialAugust 13, 2024 | finance.yahoo.comKiromic BioPharma Provides Update on Part 1 of the Deltacel-01 TrialAugust 9, 2024 | finance.yahoo.comKiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01August 1, 2024 | finance.yahoo.comKiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion PhaseJuly 20, 2024 | finance.yahoo.comKiromic BioPharma Provides Updates on its Deltacel-01 Clinical TrialJune 20, 2024 | businesswire.comKiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical TrialJune 6, 2024 | businesswire.comKiromic BioPharma's Deltacel-01 Phase 1 Trial Shows Early Efficacy At Sixth WeekMay 29, 2024 | markets.businessinsider.comKiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical TrialMay 29, 2024 | businesswire.comKiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial SiteMay 20, 2024 | businesswire.comKRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024May 13, 2024 | investorplace.comDeltacel shows promise in Kiromic BioPharma lung cancer trial, Kiromic seeks FDA fast trackApril 26, 2024 | uk.investing.comKiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three PatientsApril 24, 2024 | finance.yahoo.comKiromic BioPharma files to withdraw registration statementApril 10, 2024 | msn.comKiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical TrialApril 2, 2024 | businesswire.comEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical TrialMarch 19, 2024 | finance.yahoo.comEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical TrialMarch 19, 2024 | businesswire.comKiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialMarch 1, 2024 | businesswire.comKiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7thFebruary 28, 2024 | finance.yahoo.comKiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7thFebruary 28, 2024 | businesswire.comResults from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two MonthsFebruary 14, 2024 | finance.yahoo.comResults from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two MonthsFebruary 14, 2024 | businesswire.comKiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung CancerJanuary 29, 2024 | finance.yahoo.comKiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical TrialJanuary 5, 2024 | finance.yahoo.comKiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung CancerDecember 14, 2023 | finance.yahoo.comKiromic BioPharma Announces Uplisting to OTCQB MarketNovember 16, 2023 | finance.yahoo.comKiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer CenterNovember 9, 2023 | finance.yahoo.comKiromic BioPharma Inc Ordinary SharesNovember 1, 2023 | morningstar.comKiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial AgreementOctober 23, 2023 | finance.yahoo.comStaidson Beijing Biopharma (300204)September 15, 2023 | uk.investing.comKiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14September 13, 2023 | finance.yahoo.comKiromic BioPharma Welcomes Two New Directors to its BoardJuly 24, 2023 | finance.yahoo.comTrading was temporarily halted for "KRBP" at 09:07 AM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "KRBP" at 09:07 AM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comKiromic Biopharma Shares Down 12% After Stock Offering ProspectusJune 30, 2023 | marketwatch.comFounder of multibillion-dollar drug developer Array BioPharma leads Boulder oncology startup in $54M financing roundJune 10, 2023 | bizjournals.com Get Kiromic BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address KRBP Media Mentions By Week KRBP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KRBP News Sentiment▼-0.380.64▲Average Medical News Sentiment KRBP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KRBP Articles This Week▼20▲KRBP Articles Average Week Get Kiromic BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMCC News Today VINC News Today PPBT News Today ALLR News Today SONN News Today SNPX News Today BNOX News Today ONCO News Today PRTG News Today PHIO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KRBP) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiromic BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiromic BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
